Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Cleveland-based regenerative medicine company also is making changes to its executive team in a restructuring plan that it said is designed to 'reduce costs and prioritize lead clinical programs.'
Athersys Inc. (ATHX) has initiated a restructuring plan after a study disappointed while cash reserves are dwindling.
Athersys (NASDAQ:ATHX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs […]
Stock Analysts’ upgrades for Wednesday, June 1st: Applied Therapeutics (NASDAQ:APLT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.50 target price on the stock. According to Zacks, “Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet […]
Analysts’ new coverage for Tuesday, May 31st: The Goldman Sachs Group, Inc. initiated coverage on shares of ABN AMRO Bank (OTCMKTS:AAVMY). The firm issued a neutral rating and a €13.25 ($14.25) price target on the stock. StockNews.com began coverage on shares of Acme United (NYSE:ACU). StockNews.com issued a hold rating on the stock. Berenberg Bank […]